Open-label Phase 3 data linked Cobenfy to lower hallucination and delusion scores in Alzheimer’s patients, but the lack of placebo controls prevents conclusions about the drug’s effectiveness.
Schizophrenia Drug Cobenfy Cut Hallucination and Delusion Scores in Alzheimer’s Patients, but These Open-Label Phases Lacked a Placebo
by | Nov 22, 2026 | Uncategorized | 0 comments

Recent Comments